'For the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Gland Pharma has increased 64.68% to Rs 1545.16 crore compared to quarter ended Dec 2022.  Operating profit margin has declined from 30.86% to 23.06%, leading to 23.08% rise in operating profit to Rs 356.39 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 45.68% to 32.76%.   Purchase of finished goods cost rose from 0.41% to 0.45%.   Employee cost increased from 10.67% to 24.38%.   Other expenses rose from 12.71% to 17.24%.   Power and Oil fuel cost rose from 3.08% to 4.52%.   

Other income fell 39.21% to Rs 37.39 crore.  PBIDT rose 12.16% to Rs 393.78 crore.  Provision for interest rose 101.53% to Rs 5.28 crore.  

PBDT rose 11.49% to Rs 388.5 crore.  Provision for depreciation rose 180.09% to Rs 105.34 crore.  

• 

  (12-Jul-2025)

  Elecon Engineering Company

  Net up 139% inflated by higher one off income
• 

  (12-Jul-2025)

  Avenue Supermarts

  Revenue up 16.3% YoY to Rs 16359.7 crore, Net profit flat at Rs 773 crore in Q1FY2026
• 

  (11-Jul-2025)

  Tata Consultancy Services

  Revenue up 1.3% YoY to Rs 63437 crore in Q1FY2026
• 

  (11-Jul-2025)

  Tata Elxsi

  Revenue down 3.7% YoY to Rs 892.1 crore in Q1FY2026